Clinical trial
WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With…
NCT00129545 · Boston Scientific Corporation, Industry · Completed
Key facts
| NCT number | NCT00129545 |
|---|---|
| Title | WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation |
| Official title | WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation (PROTECT AF) |
| Lead sponsor | Boston Scientific Corporation, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Atrial Fibrillation, Stroke |
| Intervention type | Device, Drug |
| Interventions | WATCHMAN Left Atrial Appendage Closure Technology, Warfarin |
| Enrollment | 800 |
| Start date | Feb 1, 2005 |
| Primary completion | Aug 1, 2013 |
| Completion | May 1, 2014 |
| First posted | Aug 12, 2005 |
| Last update posted | May 15, 2015 |
| Countries | Czechia, Germany, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: